А new drug in the complex therapy of diabetes mellitus. Post-registration experience in patients with type 1 and type 2 diabetes mellitus
| Autor: | S. V. Vorob'yev, E. U. Petrovskaya, N. A. Kuz'menko, I. A. Khripun |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 16, Pp 86-92 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2018-16-86-92 |
| Popis: | Diabetes mellitus (DM), due to its high incidence and prevalence, presents an urgent problem for the scientific community, which requires new ways of treating and preventing complications. Existing hypoglycemic treatment approaches do not always contribute to the achievement of glycaemic targets.Objective. Study of Subetta-based therapy for patients with DM 1 and DM 2 in real-life clinical practice.Materials and methods. The program involved 71 patients with DM 1 and 289 patients with DM 2, HbA1c ≥ 7.0%, who took Subetta in combination therapy of diabetes. The duration of the program was 12 weeks. The laboratory examination included the determination of the level of HbA1c, fasting plasma glucose.Results. The administration of Subetta in complex therapy of DM 1 and DM 2 led to a significant reduction in HbA1c from 9.2 ± 1.85 to 8.13 ± 1.29 mmol/L and from 8.62 ± 1.54 to 7.49 ± 1.1 mmol/L, respectively (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|